Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8791552 | 0.80 | EPHX1 (0.55) | EPHX1 | |
| SCHEMBL28227694 | 0.79 | EPHX1 (0.59) | EPHX1 | |
| SCHEMBL28227693 | 0.79 | EPHX1 (0.59) | EPHX1 | |
| SCHEMBL14374937 | 0.76 | — | — | |
| SCHEMBL10202271 | 0.76 | — | — | |
| SCHEMBL24115804 | 0.76 | — | — | |
| SCHEMBL4356819 | 0.74 | — | — | |
| SCHEMBL16827243 | 0.74 | — | — | |
| SCHEMBL5797801 | 0.74 | EPHX1 (0.48) | EPHX1CA1CA2CA4ADRA2A | |
| SCHEMBL29754642 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556858-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190119202-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20180028553-A1 | USE OF STING AGONIST AS CANCER TREATMENT | THE UNIVERSITY OF CHICAGO | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028553-A1 | USE OF STING AGONIST AS CANCER TREATMENT | STING1, IRF3, IFNAR1 | EPHX1 2870/4885CA1 4875/4885CA2 4720/4885 |
| US-20190119202-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | EPHX1 1518/4885CA1 3954/4885CA2 3897/4885 |
| US-10556858-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | IL17A, ALOX15, ALOX12 | EPHX1 1518/4885CA1 3954/4885CA2 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.